Natera reported second quarter 2026 financial results with total revenues of $752.8 million, a 37.7% increase from the prior year period. The company processed approximately 1,043,900 tests, including roughly 296,700 oncology tests, while achieving a gross margin of 64.5%. Natera raised its full-year 2026 revenue guidance midpoint by $100 million to $2.85 billion–$2.91 billion and reported a net loss of $67.0 million, or ($0.47) per diluted share. The company operates in the precision medicine and genetic testing industry.

Monica Bertagnolli resigned from the Board of Directors and all associated committees of Natera, Inc., effective July 1, 2026. Her departure was due to her new position with the National Academy of Medicine and was not related to any disagreements regarding company operations, policies, or practices. Natera, Inc. is a healthcare company specializing in genetic testing.

Natera, Inc. expanded its Board of Directors from eleven to twelve members and appointed Thomas Lynch as a Class I director, effective June 2, 2026. Dr. Lynch will serve on the Human Capital Committee and will receive compensation consistent with other non-employee directors. Natera, Inc. operates in the healthcare technology sector, providing genetic testing services.

On June 11, 2026, Natera, Inc. held its Annual Meeting of Stockholders, where shareholders approved an amendment to the Amended and Restated 2015 Equity Incentive Plan. This amendment increases the shares reserved for issuance under the plan by 3.2 million shares of common stock. Other routine matters, including the election of directors Rowan Chapman, Herm Rosenman, Jonathan Sheena, and Eric H. Rubin, the ratification of Ernst & Young LLP as independent auditor, and advisory votes on executive compensation, were also approved. Natera operates in the healthcare industry, providing genetic testing and diagnostics.